Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

January 17, 2002

Slides

AvaproŽ (Irbesartan) in Type 2 Diabetic Renal Disease

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

AvaproŽ (Irbesartan) in Type 2 Diabetic Renal Disease, Introduction, Brian F Daniels, MD, Pharmaceutical Research Institute, Bristol-Myers Squibb   pdf

Disease Background, Edmund J Lewis, MD, Muehrcke Professor of Nephrology and Director of the Section of Nephrology, Rush Medical College   pdf

IDNT Irbesartan Diabetic Nephropathy Trial, Melissa Cooper, MD, MS, Pharmaceutical Research Institute, Bristol-Myers Squibb   pdf

IRMA2 IRbesartan MicroAlbuminuria in Type 2 Diabetic Subjects, Hans-Henrik Parving, MD, DMSc, Professor and Chief Physician, Steno Diabetes Center   pdf

Benefit: Risk Assessment, Edmund J Lewis, MD, Muehrcke Professor of Nephrology and Director of the Section of Nephrology, Rush Medical College   pdf